Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes-Reference-Cited by-同舟云学术

Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes

Published:2005-05-12 Issue:6 Volume:48 Page:1093-1104
ISSN:0012-186X
Container-title:Diabetologia
language:en
Short-container-title:Diabetologia

Author:

Charbonnel B.,Schernthaner G.,Brunetti P.,Matthews D. R.,Urquhart R.,Tan M. H.,Hanefeld M.

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00125-005-1751-1.pdf

Reference36 articles.

1. Groop LC (1992) Sulfonylureas in NIDDM. Diabetes Care 15:737–754

2. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC, UK Prospective Diabetes Study (UKPDS) Group (1998) UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. Diabet Med 15:297–303

3. Turner RC (1998) The U.K. prospective diabetes study: a review. Diabetes Care 21(Suppl 3):C35–C38

4. UK Prospective Diabetes Study Group (1995) UK prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes 44:1249–1258

5. Turner RC, Cull CA, Frighi V, Holman RR, the UK Prospective Diabetes Study (UKPDS) Group (1999) Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 281:2005–2012

Cited by 137 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metformin for preventing the progression of chronic kidney disease;Cochrane Database of Systematic Reviews;2024-06-04

2. Cost-effective Analysis of Prescribed Oral Hypoglycemic Agents amongst Pre-obese and Obese Diabetic Patients in a Tertiary Care Hospital in Odisha;Global Journal of Medical, Pharmaceutical, and Biomedical Update;2023-07-04

3. Diabetes Mellitus: From Definition to Therapy;Clinical and Laboratory Medicine Textbook;2023

4. Cost-effectiveness and budget impact analysis of fixed combination of alogliptin and pioglitazone in the treatment of type 2 diabetes mellitus;Medical Technologies. Assessment and Choice;2023

5. 2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care;Primary Care Diabetes;2022-04